Bridge­Bio grabs a sec­ond pri­or­i­ty re­view for the port­fo­lio — giv­ing Per­cep­tive start­up cause to cel­e­brate

Just weeks af­ter get­ting its first NDA in — and grab­bing pri­or­i­ty re­view from the FDA in the process — Bridge­Bio says it’s lined up a sec­ond po­ten­tial speedy ap­proval for the port­fo­lio.

The hon­or goes to Bridge­Bio af­fil­i­ate QED Ther­a­peu­tics, which is de­vel­op­ing in­fi­gra­tinib as a cholan­gio­car­ci­no­ma treat­ment. In par­tic­u­lar, it had filed for ap­proval in sec­ond- and lat­er-line use.

It’s al­so good news for Lian­Bio, the Per­cep­tive start­up boast­ing a new mod­el for bring­ing West­ern drugs to Chi­na. In­fi­gra­tinib is one of the an­chor drugs of its in-li­censed port­fo­lio; in fact, Bridge­Bio CEO Neil Ku­mar has point­ed to the pro­gram as an ex­am­ple of Lian­Bio’s cre­ative strate­gies in tai­lor­ing de­vel­op­ment pro­grams for Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.